Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

Fig. 5

Effectiveness of serum SV2A and other biomarkers for AD risk individual identification. (a) Efficacy of serum SV2A, NfL, GFAP, and p-tau217 in differentiating cognitively unimpaired APOE ε4 carriers from cognitively unimpaired APOE ε4 non-carriers, respectively. (b) Efficacy of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in differentiating cognitively unimpaired APOE ε4 carriers from cognitively unimpaired APOE ε4 non-carriers, respectively. Abbreviations: 95% CI, 95% confidence interval; APOE ε4 −/−, APOE ε4 non-carriers; APOE ε4 +/−, APOE ε4 carriers; AUC, area under the curve; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau; SV2A, synaptic vesicle glycoprotein 2 A; vs., versus

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193